NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.
Workspace · Cancer algorithms
Known population prevalences from ACS 2026 / SEER Stat Facts, wired to Screening, Surveillance, and Toxicity scenarios on four golden fixtures (Walter, Priya, Noah, Rio). Seven evaluators already in the repo, plus cited stubs from the SEER common-sites table. Existing evaluators only — PLCOm2012, Gail-class, USPSTF/ACS tables, COG/ASCO flags. Not FDA-cleared. Not a diagnosis. Synthetic fixtures only.
NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.
Site-by-site Acute toxicities / Late toxicities / Named conditions to monitor live on Late toxicity printouts. Cadences are placeholders. GTD is out of domain.
Official empty later-cancer notes
Cited empty sentences only. Not a later-cancer engine. Kidney and thyroid stay unmapped without an invented empty note.
The cited adult brain after-treatment page still has no official later-cancer sentence.
Official copy: there is no standard staging system for leukemia.
Anthracycline and bleomycin stay unnamed as myeloma-specific.
Living with cancer · SEER 2023
Population counts from site Stat Facts. Not a personal risk. Cervix stays interval-only. Hodgkin stays flags + Ann Arbor.
Female breast · SEER 2023
4,238,585
women living with this cancer. Median age at diagnosis 64 · at death 71.
Female breast algorithm →ACS follow-up tests named here: Echoes after cardiotoxic chemo · Yearly mammograms plus breast MRIs after chest radiation before age 30
Prostate · SEER 2023
3,700,086
men living with this cancer. Median age at diagnosis 68 · at death 79.
Prostate algorithm →ACS follow-up tests named here: Echoes after cardiotoxic chemo
Melanoma of the skin · SEER 2023
1,573,288
people living with this cancer. Median age at diagnosis 67 · at death 73.
Melanoma of the skin algorithm →Treatment summary for later problems
Colon and rectum · SEER 2023
1,478,528
people living with this cancer. Median age at diagnosis 66 · at death 72.
Colon and rectum algorithm →Bowel obstruction from adhesions · Urinary retention or incontinence after pelvis RT · Fertility after pelvis, belly, or spine RT · Sexuality after cancer treatment · Cavities and tooth loss after chemo · Cognitive impairment after brain RT or chemo
Lung and bronchus · SEER 2023
661,853
people living with this cancer. Median age at diagnosis 71 · at death 73.
Lung and bronchus algorithm →ACS follow-up tests named here: Lung function tests after some chemo or a stem-cell or bone-marrow transplant · Echoes after cardiotoxic chemo · Yearly mammograms plus breast MRIs after chest radiation before age 30
Cervix · SEER 2023
305,284
women living with this cancer. Median age at diagnosis 50 · at death 60. Lifetime ≈ 0.6%. SEER Stat Facts: women living with cervical cancer in the United States in 2023.
Cervix algorithm →Low estrogen after pelvic treatment · Osteoporosis after hormone-affecting treatment · Low estrogen or testosterone after hormone-affecting treatment · Osteonecrosis of the jaw after bisphosphonates · Vision change after hormone therapy · Lymphedema after pelvic-node surgery or RT
Hodgkin lymphoma · SEER 2023
240,775
people living with this cancer. Median age at diagnosis 38 · at death 72. Lifetime ≈ 0.2%. SEER Stat Facts: people living with Hodgkin lymphoma in the United States in 2023.
Hodgkin lymphoma algorithm →ACS follow-up tests named here: Yearly thyroid exam after head, neck, or throat radiation · Lung function tests after some chemo or a stem-cell or bone-marrow transplant · Echoes after cardiotoxic chemo · Yearly mammograms plus breast MRIs after chest radiation before age 30
Anthracycline and bleomycin stay unnamed as myeloma-specific.
Cited stubs with a 2023 living count
Official site Stat Facts only. Still not encoded — no screening interval and no unpublished coefficient.
Urinary bladder · SEER 2023
763,031
people living with this cancer. Median age at diagnosis 73 · at death 79. Lifetime ≈ 2.1% (SEER Stat Facts). 763,031 people living with bladder cancer in 2023. No encoded screening interval. Mortality is 4.1 per 100k, never an artboard percent.
Urinary bladder algorithm →ACS follow-up tests named here: Echoes after cardiotoxic chemo
Non-Hodgkin lymphoma (heme stub) · SEER 2023
872,940
people living with this cancer. Median age at diagnosis 68 · at death 76. Lifetime ≈ 2.0% (SEER Stat Facts). 872,940 people living with NHL in 2023. NHL pin only — leukemia and myeloma are not this row. Not a Hodgkin incidence model.
Non-Hodgkin lymphoma (heme stub) algorithm →ACS follow-up tests named here: Yearly thyroid exam after head, neck, or throat radiation · Lung function tests after some chemo or a stem-cell or bone-marrow transplant · Echoes after cardiotoxic chemo · Yearly mammograms plus breast MRIs after chest radiation before age 30
Anthracycline and bleomycin stay unnamed as myeloma-specific.
Pancreas · SEER 2023
113,931
people living with this cancer. Median age at diagnosis 71 · at death 73. Lifetime ≈ 1.7% (SEER Stat Facts). 113,931 people living with pancreatic cancer in 2023. Third-deadliest site by ACS 2026 deaths. No encoded screening interval.
Pancreas algorithm →Bowel obstruction from adhesions · Urinary retention or incontinence after pelvis RT · Fertility after pelvis, belly, or spine RT · Sexuality after cancer treatment · Cavities and tooth loss after chemo · Cognitive impairment after brain RT or chemo
Thyroid · SEER 2023
1,035,274
people living with this cancer. Median age at diagnosis 51 · at death 74. 1,035,274 people living with thyroid cancer in 2023 (SEER Stat Facts). Lifetime is not restated here — it collides with a locked artboard figure. No encoded screening interval.
Thyroid algorithm →No invented printout field. Complementary ACS follow-up-care and late-effects pointers stay on this page.
Liver and intrahepatic bile duct · SEER 2023
116,514
people living with this cancer. Median age at diagnosis 68 · at death 70. 116,514 people living with this cancer in 2023 (SEER Stat Facts). Lifetime is not restated here — it collides with a locked artboard figure. No encoded screening interval.
Liver and intrahepatic bile duct algorithm →Bowel obstruction from adhesions · Urinary retention or incontinence after pelvis RT · Fertility after pelvis, belly, or spine RT · Sexuality after cancer treatment · Cavities and tooth loss after chemo · Cognitive impairment after brain RT or chemo
Esophagus · SEER 2023
55,281
people living with this cancer. Median age at diagnosis 69 · at death 71. Lifetime ≈ 0.5% (SEER Stat Facts). 55,281 people living with esophageal cancer in 2023. Share of all new cases is not restated here. No encoded screening interval.
Esophagus algorithm →Bowel obstruction from adhesions · Urinary retention or incontinence after pelvis RT · Fertility after pelvis, belly, or spine RT · Sexuality after cancer treatment · Cavities and tooth loss after chemo · Cognitive impairment after brain RT or chemo
Ovary · SEER 2023
254,621
women living with this cancer. Median age at diagnosis 63 · at death 71. 254,621 women living with ovarian cancer in 2023 (SEER Stat Facts). Lifetime is not restated here — it collides with a locked artboard figure. No encoded screening interval. Not a CA-125 engine.
Ovary algorithm →Low estrogen after pelvic treatment · Osteoporosis after hormone-affecting treatment · Low estrogen or testosterone after hormone-affecting treatment · Osteonecrosis of the jaw after bisphosphonates · Vision change after hormone therapy · Lymphedema after pelvic-node surgery or RT
Kidney and renal pelvis · SEER 2023
687,999
people living with this cancer. Median age at diagnosis 65 · at death 73. Lifetime ≈ 1.8% (SEER Stat Facts). 687,999 people living with kidney and renal pelvis cancer in 2023. No encoded screening interval. Not a VHL formula.
Kidney and renal pelvis algorithm →No invented printout field. Complementary ACS follow-up-care and late-effects pointers stay on this page.
Corpus and uterus, NOS · SEER 2023
890,295
women living with this cancer. Median age at diagnosis 64 · at death 71. Lifetime ≈ 3.1% among women (SEER Stat Facts). 890,295 women living with uterine cancer in 2023. No encoded screening interval.
Corpus and uterus, NOS algorithm →Low estrogen after pelvic treatment · Osteoporosis after hormone-affecting treatment · Low estrogen or testosterone after hormone-affecting treatment · Osteonecrosis of the jaw after bisphosphonates · Vision change after hormone therapy · Lymphedema after pelvic-node surgery or RT
Leukemia · SEER 2023
563,581
people living with this cancer. Median age at diagnosis 68 · at death 76. Lifetime ≈ 1.6% (SEER Stat Facts). 563,581 people living with leukemia in 2023. Separate from the NHL heme stub. No invented incidence formula.
Leukemia algorithm →No invented printout field. Complementary ACS follow-up-care and late-effects pointers stay on this page.
Official copy: there is no standard staging system for leukemia.
Oral cavity and pharynx · SEER 2023
461,008
people living with this cancer. Median age at diagnosis 65 · at death 70. Lifetime ≈ 1.2% (SEER Stat Facts). 461,008 people living with oral cavity and pharynx cancer in 2023. No encoded screening interval.
Oral cavity and pharynx algorithm →ACS follow-up tests named here: Yearly thyroid exam after head, neck, or throat radiation
Myeloma · SEER 2023
202,793
people living with this cancer. Median age at diagnosis 69 · at death 76. Lifetime ≈ 0.8% (SEER Stat Facts). 202,793 people living with myeloma in 2023. Separate from the NHL heme stub and from leukemia. No invented incidence formula.
Myeloma algorithm →ACS follow-up tests named here: Yearly thyroid exam after head, neck, or throat radiation · Lung function tests after some chemo or a stem-cell or bone-marrow transplant · Echoes after cardiotoxic chemo · Yearly mammograms plus breast MRIs after chest radiation before age 30
Anthracycline and bleomycin stay unnamed as myeloma-specific.
Stomach · SEER 2023
150,727
people living with this cancer. Median age at diagnosis 68 · at death 71. Lifetime ≈ 0.8% (SEER Stat Facts). 150,727 people living with stomach cancer in 2023. No encoded screening interval.
Stomach algorithm →Bowel obstruction from adhesions · Urinary retention or incontinence after pelvis RT · Fertility after pelvis, belly, or spine RT · Sexuality after cancer treatment · Cavities and tooth loss after chemo · Cognitive impairment after brain RT or chemo
Brain and other nervous system · SEER 2023
196,343
people living with this cancer. Median age at diagnosis 61 · at death 67. Lifetime ≈ 0.6% (SEER Stat Facts). 196,343 people living with this cancer in 2023. No encoded screening interval. Not a glioma grade engine.
Brain and other nervous system algorithm →ACS follow-up tests named here: Yearly thyroid exam after head, neck, or throat radiation
The cited adult brain after-treatment page still has no official later-cancer sentence.
Testis · SEER 2023
325,990
men living with this cancer. Median age at diagnosis 33 · at death 40. Lifetime ≈ 0.4% among men (SEER Stat Facts). 325,990 men living with testicular cancer in 2023. No encoded screening interval.
Testis algorithm →ACS follow-up tests named here: Echoes after cardiotoxic chemo
Small intestine · SEER 2023
93,952
people living with this cancer. Median age at diagnosis 66 · at death 73. Lifetime ≈ 0.3% (SEER Stat Facts). 93,952 people living with small intestine cancer in 2023. No encoded screening interval.
Small intestine algorithm →Bowel obstruction from adhesions · Urinary retention or incontinence after pelvis RT · Fertility after pelvis, belly, or spine RT · Sexuality after cancer treatment · Cavities and tooth loss after chemo · Cognitive impairment after brain RT or chemo
Larynx · SEER 2023
87,355
people living with this cancer. Median age at diagnosis 67 · at death 70. Lifetime ≈ 0.3% (SEER Stat Facts). 87,355 people living with laryngeal cancer in 2023. No encoded screening interval.
Larynx algorithm →ACS follow-up tests named here: Yearly thyroid exam after head, neck, or throat radiation
Anus · SEER 2023
88,564
people living with this cancer. Median age at diagnosis 65 · at death 69. Lifetime ≈ 0.2% (SEER Stat Facts). 88,564 people living with anal cancer in 2023. No encoded screening interval.
Anus algorithm →Bowel obstruction from adhesions · Urinary retention or incontinence after pelvis RT · Fertility after pelvis, belly, or spine RT · Sexuality after cancer treatment · Cavities and tooth loss after chemo · Cognitive impairment after brain RT or chemo
Bone and joint · SEER 2023
65,261
people living with this cancer. Median age at diagnosis 48 · at death 67. Lifetime ≈ 0.1% (SEER Stat Facts). 65,261 people living with bone and joint cancer in 2023. Incidence stays a rate per 100k. No encoded screening interval.
Bone and joint algorithm →ACS follow-up tests named here: Echoes after cardiotoxic chemo · Lung function tests after some chemo or a stem-cell or bone-marrow transplant
Soft tissue including heart · SEER 2023
181,366
people living with this cancer. Median age at diagnosis 63 · at death 68. Lifetime ≈ 0.3% (SEER Stat Facts). 181,366 people living with soft tissue including heart cancer in 2023. Female death rate stays a rate per 100k. No encoded screening interval.
Soft tissue including heart algorithm →ACS follow-up tests named here: Echoes after cardiotoxic chemo · Lung function tests after some chemo or a stem-cell or bone-marrow transplant
Hodgkin · Ann Arbor 5-year relative survival
I 92.7% · II 95.4% · III 87.7% · IV 82.8% · all 89.3%
Ann Arbor I–IV. Not localized / regional / distant.
Golden four · Screening fit
Walter, Priya, Noah, and Rio — synthetic only. Same Screening · Surveillance · Toxicity nav. No unpublished coefficient.
| Cancer | Rio | Noah | Walter | Priya |
|---|---|---|---|---|
| Female breastBreast printout → | On plan | Out of domain | Out of domain | On plan |
| Lung and bronchusLung printout → | Out of domain | Out of domain | On plan | Out of domain |
| Colon and rectumGI printout → | On plan | On plan | On plan | On plan |
| ProstateProstate printout → | Out of domain | On plan | On plan | Out of domain |
| Melanoma of the skinSkin printout → | Empty | On plan | Empty | Empty |
| CervixGYN printout → | On plan | Out of domain | Out of domain | On plan |
| Hodgkin lymphomaLymphoma / myeloma fields printout → | On plan | Out of domain | Out of domain | Out of domain |
Golden four · Surveillance fit
Walter, Priya, Noah, and Rio — synthetic only. Same Screening · Surveillance · Toxicity nav. No unpublished coefficient.
| Cancer | Rio | Noah | Walter | Priya |
|---|---|---|---|---|
| Female breastBreast printout → | Empty | Out of domain | Out of domain | Empty |
| Lung and bronchusLung printout → | Out of domain | Out of domain | Empty | Out of domain |
| Colon and rectumGI printout → | Empty | Empty | Empty | Empty |
| ProstateProstate printout → | Out of domain | Empty | Empty | Out of domain |
| Melanoma of the skinSkin printout → | Empty | On plan | Empty | Empty |
| CervixGYN printout → | Empty | Out of domain | Out of domain | Empty |
| Hodgkin lymphomaLymphoma / myeloma fields printout → | On plan | Out of domain | Out of domain | Out of domain |
Golden four · Toxicity fit
Walter, Priya, Noah, and Rio — synthetic only. Same Screening · Surveillance · Toxicity nav. No unpublished coefficient.
| Cancer | Rio | Noah | Walter | Priya |
|---|---|---|---|---|
| Female breastBreast printout → | On plan | Out of domain | Out of domain | Empty |
| Lung and bronchusLung printout → | Out of domain | Out of domain | Empty | Out of domain |
| Colon and rectumGI printout → | Empty | Empty | Empty | Empty |
| ProstateProstate printout → | Out of domain | Empty | Empty | Out of domain |
| Melanoma of the skinSkin printout → | On plan | Empty | Empty | Empty |
| CervixGYN printout → | Empty | Out of domain | Out of domain | Empty |
| Hodgkin lymphomaLymphoma / myeloma fields printout → | On plan | Out of domain | Out of domain | Out of domain |
Screening · Surveillance · Toxicity fit · Rio · Plan — survivor
Mapped onto cards already shown for this synthetic fixture. Stubs are cited population pins only.
| Cancer | Screening | Surveillance | Toxicity |
|---|---|---|---|
| Female breastBreast printout → | On plan | Empty | On plan |
| Lung and bronchusLung printout → | Out of domain | Out of domain | Out of domain |
| Colon and rectumGI printout → | On plan | Empty | Empty |
| ProstateProstate printout → | Out of domain | Out of domain | Out of domain |
| Melanoma of the skinSkin printout → | Empty | Empty | On plan |
| CervixGYN printout → | On plan | Empty | Empty |
| Hodgkin lymphomaLymphoma / myeloma fields printout → | On plan | On plan | On plan |
21 v2 stubs cited, not encoded: Urinary bladder, Non-Hodgkin lymphoma (heme stub), Pancreas, Thyroid, Liver and intrahepatic bile duct, Esophagus, Ovary, Kidney and renal pelvis, Corpus and uterus, NOS, Leukemia, Oral cavity and pharynx, Myeloma, Stomach, Brain and other nervous system, Testis, Small intestine, Larynx, Anus, Vulva, Bone and joint, Soft tissue including heart.
Screening · Surveillance · Toxicity fit · Noah · Plan — skin cancer
Mapped onto cards already shown for this synthetic fixture. Stubs are cited population pins only.
| Cancer | Screening | Surveillance | Toxicity |
|---|---|---|---|
| Female breastBreast printout → | Out of domain | Out of domain | Out of domain |
| Lung and bronchusLung printout → | Out of domain | Out of domain | Out of domain |
| Colon and rectumGI printout → | On plan | Empty | Empty |
| ProstateProstate printout → | On plan | Empty | Empty |
| Melanoma of the skinSkin printout → | On plan | On plan | Empty |
| CervixGYN printout → | Out of domain | Out of domain | Out of domain |
| Hodgkin lymphomaLymphoma / myeloma fields printout → | Out of domain | Out of domain | Out of domain |
21 v2 stubs cited, not encoded: Urinary bladder, Non-Hodgkin lymphoma (heme stub), Pancreas, Thyroid, Liver and intrahepatic bile duct, Esophagus, Ovary, Kidney and renal pelvis, Corpus and uterus, NOS, Leukemia, Oral cavity and pharynx, Myeloma, Stomach, Brain and other nervous system, Testis, Small intestine, Larynx, Anus, Vulva, Bone and joint, Soft tissue including heart.
Screening · Surveillance · Toxicity fit · Walter · S1 prostate
Mapped onto cards already shown for this synthetic fixture. Stubs are cited population pins only.
| Cancer | Screening | Surveillance | Toxicity |
|---|---|---|---|
| Female breastBreast printout → | Out of domain | Out of domain | Out of domain |
| Lung and bronchusLung printout → | On plan | Empty | Empty |
| Colon and rectumGI printout → | On plan | Empty | Empty |
| ProstateProstate printout → | On plan | Empty | Empty |
| Melanoma of the skinSkin printout → | Empty | Empty | Empty |
| CervixGYN printout → | Out of domain | Out of domain | Out of domain |
| Hodgkin lymphomaLymphoma / myeloma fields printout → | Out of domain | Out of domain | Out of domain |
21 v2 stubs cited, not encoded: Urinary bladder, Non-Hodgkin lymphoma (heme stub), Pancreas, Thyroid, Liver and intrahepatic bile duct, Esophagus, Ovary, Kidney and renal pelvis, Corpus and uterus, NOS, Leukemia, Oral cavity and pharynx, Myeloma, Stomach, Brain and other nervous system, Testis, Small intestine, Larynx, Anus, Vulva, Bone and joint, Soft tissue including heart.
Screening · Surveillance · Toxicity fit · Priya · average-risk
Mapped onto cards already shown for this synthetic fixture. Stubs are cited population pins only.
| Cancer | Screening | Surveillance | Toxicity |
|---|---|---|---|
| Female breastBreast printout → | On plan | Empty | Empty |
| Lung and bronchusLung printout → | Out of domain | Out of domain | Out of domain |
| Colon and rectumGI printout → | On plan | Empty | Empty |
| ProstateProstate printout → | Out of domain | Out of domain | Out of domain |
| Melanoma of the skinSkin printout → | Empty | Empty | Empty |
| CervixGYN printout → | On plan | Empty | Empty |
| Hodgkin lymphomaLymphoma / myeloma fields printout → | Out of domain | Out of domain | Out of domain |
21 v2 stubs cited, not encoded: Urinary bladder, Non-Hodgkin lymphoma (heme stub), Pancreas, Thyroid, Liver and intrahepatic bile duct, Esophagus, Ovary, Kidney and renal pelvis, Corpus and uterus, NOS, Leukemia, Oral cavity and pharynx, Myeloma, Stomach, Brain and other nervous system, Testis, Small intestine, Larynx, Anus, Vulva, Bone and joint, Soft tissue including heart.
NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.
In-page filter only — primary nav stays Screening | Surveillance | Toxicity. Each implemented row reuses an existing evaluator. v2 stubs carry ACS/SEER counts only. No unpublished coefficients. Synthetic fixtures only.
algo-breast · evaluateBreast · Gail-class-approx
Female breast · 321,910 new · 42,140 deaths (ACS 2026) · mortality 18.9 per 100k · 5-yr RS 91.9% (SEER)
Birth-to-death 13.0% (1 in 8) among females (ACS Table 6). Plus 2,670 male cases (ACS 2026).
Screening scenario
USPSTF 2024 biennial mammography 40–74
On this fixture: 0.67 educational % · on this plan
relative risk ×1.21 · USPSTF 2024 biennial mammography 40–74
NOT official BCRAT. The composed 15-screen evidence figure stays on the artboard and is not recomputed here.
Osteoporosis after hormone-affecting treatment · Low estrogen or testosterone after hormone-affecting treatment · Osteonecrosis of the jaw after bisphosphonates · Vision change after hormone therapy · Cavities and tooth loss after chemo · Peripheral neuropathy after chemo · Cognitive impairment after brain RT or chemo · Heart problems after some cardiotoxic treatments · Lymphedema after lymph-node surgery or radiation · Lymphedema after node surgery or RT
ACS follow-up tests named here: Echoes after cardiotoxic chemo · Yearly mammograms plus breast MRIs after chest radiation before age 30
algo-lung · evaluateLung · PLCOm2012+USPSTF-2021
Lung and bronchus · 229,410 new · 124,990 deaths (ACS 2026) · mortality 30.2 per 100k · 5-yr RS 29.5% (SEER)
Birth-to-death 5.4% (1 in 19) in both sexes (ACS Table 6).
Screening scenario
USPSTF 2021 LDCT + published PLCOm2012
On this fixture: — · out of domain · out of domain
0 pack-years · never · does not meet USPSTF 2021 LDCT criteria
Never-smokers are out of PLCOm2012 scope. Score does not override USPSTF eligibility.
Heart problems after chest or lung RT · Lung problems after bleomycin, busulfan, or chest RT · Hearing loss after high-dose platinum chemo · Cavities and tooth loss after chemo · Peripheral neuropathy after chemo · Cognitive impairment after brain RT or chemo · Heart problems after some cardiotoxic treatments
ACS follow-up tests named here: Lung function tests after some chemo or a stem-cell or bone-marrow transplant · Echoes after cardiotoxic chemo · Yearly mammograms plus breast MRIs after chest radiation before age 30
algo-colorectal · evaluateColorectal · USPSTF-2021+points
Colon and rectum · 158,850 new · 55,230 deaths (ACS 2026) · mortality 12.7 per 100k · 5-yr RS 65.4% (SEER)
Birth-to-death 4.0% men / 3.8% women (ACS Table 6).
Screening scenario
USPSTF 2021 start at 45 (40 if first-degree CRC)
On this fixture: 0.00 educational % · on this plan
average-risk screening · choose FIT yearly or colonoscopy every 10 years · outside screening ages
Points are educational. Polyp detail is not fully encoded.
Bowel obstruction from adhesions · Urinary retention or incontinence after pelvis RT · Fertility after pelvis, belly, or spine RT · Sexuality after cancer treatment · Cavities and tooth loss after chemo · Cognitive impairment after brain RT or chemo
algo-prostate · evaluateProstate · USPSTF-2018+RR
Prostate · 333,830 new · 36,320 deaths (ACS 2026) · mortality 18.9 per 100k · 5-yr RS 98.2% (SEER)
Birth-to-death 12.9% (1 in 8) among males (ACS Table 6).
Screening scenario
USPSTF 2018 shared decision 55–69 (Grade C)
On this fixture: — · out of domain · out of domain
USPSTF prostate screening discussion is framed for men
Not PCPTRC. No PSA value. The composed 15-screen prostate figure stays on the artboard; this row uses ACS Table 6 12.9% × RR.
Low testosterone after pelvic treatment or ADT · Osteoporosis after hormone-affecting treatment · Low estrogen or testosterone after hormone-affecting treatment · Osteonecrosis of the jaw after bisphosphonates · Vision change after hormone therapy · Heart problems after ADT · Heart problems after some cardiotoxic treatments
ACS follow-up tests named here: Echoes after cardiotoxic chemo
algo-skin · evaluateSkin · USPSTF-2023+phenotype
Melanoma of the skin · 112,000 new · 8,510 deaths (ACS 2026) · mortality 2 per 100k · 5-yr RS 94.7% (SEER)
Birth-to-death 3.5% men / 2.6% women among non-Hispanic White people (ACS Table 6). Keratinocyte carcinomas are far more common and are not SEER-reportable.
Screening scenario
USPSTF 2023 I — phenotype counseling, not a population interval
On this fixture: 1 phenotype points (not incidence) · empty on purpose
Fitzpatrick 3 · no outdoor-work flag · USPSTF 2023: I statement — insufficient evidence for population visual screening
No USPSTF A/B visual screen. Phenotype points are not a SEER incidence model.
Treatment summary for later problems
algo-cervix · evaluateCervix · USPSTF-2018-cervical
Cervix · 13,490 new · 4,200 deaths (ACS 2026) · mortality 2.1 per 100k · 5-yr RS 68.8% (SEER)
Lifetime ≈ 0.6% among women (SEER Stat Facts). 305,284 women living with cervical cancer in 2023.
Screening scenario
USPSTF 2018 / ACOG interval
On this fixture: interval only — no incidence % · on this plan
ages 30–65: cytology q3 or hrHPV/co-test q5 (USPSTF 2018 / ACOG) · last exam inside the interval
People without a cervix are out of domain. 2023 prevalence 305,284 women (SEER) is a population count, not a personal risk.
Low estrogen after pelvic treatment · Osteoporosis after hormone-affecting treatment · Low estrogen or testosterone after hormone-affecting treatment · Osteonecrosis of the jaw after bisphosphonates · Vision change after hormone therapy · Lymphedema after pelvic-node surgery or RT
algo-hodgkin · evaluateHodgkinFlags · Hodgkin-COG-ASCO-flags
Hodgkin lymphoma · 8,920 new · 1,100 deaths (ACS 2026) · mortality 0.2 per 100k · 5-yr RS 89.3% (SEER)
Lifetime ≈ 0.2% (SEER Stat Facts). 240,775 people living with Hodgkin lymphoma in 2023. Stage uses Ann Arbor I–IV — not localized / regional / distant.
Screening scenario
Treatment-related breast screening after chest RT
On this fixture: flags only — no incidence % · on this plan
synthetic HL diagnosed at age 24 · 20 years out on this fixture · chest radiation flag · anthracycline flag
No Hodgkin incidence formula. Stage survival is Ann Arbor I 92.7 / II 95.4 / III 87.7 / IV 82.8 (all 89.3). 2023 prevalence 240,775.
Heart problems after anthracyclines or chest RT · Lung problems after bleomycin or chest RT · Second cancers after chemo or chest RT · Bowel or bladder problems after abdomen or pelvis treatment · Hearing loss after high-dose platinum chemo · Cavities and tooth loss after chemo · Peripheral neuropathy after chemo · Cognitive impairment after brain RT or chemo · Heart problems after some cardiotoxic treatments · Low thyroid hormones after head or neck radiation · Lung problems after bleomycin, busulfan, or chest RT · Fertility after pelvis, belly, or spine RT · Sexuality after cancer treatment
ACS follow-up tests named here: Yearly thyroid exam after head, neck, or throat radiation · Lung function tests after some chemo or a stem-cell or bone-marrow transplant · Echoes after cardiotoxic chemo · Yearly mammograms plus breast MRIs after chest radiation before age 30
Anthracycline and bleomycin stay unnamed as myeloma-specific.
Cited · not encoded (v2 stubs)
Grouped ACS/SEER pins only. Open a site for Screening · Surveillance · Toxicity copy. Mortality is never printed as an artboard percent. 21 cited stubs.
Gastrointestinal · cited, not encoded
Bowel obstruction from adhesions · Urinary retention or incontinence after pelvis RT · Fertility after pelvis, belly, or spine RT · Sexuality after cancer treatment · Cavities and tooth loss after chemo · Cognitive impairment after brain RT or chemo
Bowel obstruction from adhesions · Urinary retention or incontinence after pelvis RT · Fertility after pelvis, belly, or spine RT · Sexuality after cancer treatment · Cavities and tooth loss after chemo · Cognitive impairment after brain RT or chemo
Bowel obstruction from adhesions · Urinary retention or incontinence after pelvis RT · Fertility after pelvis, belly, or spine RT · Sexuality after cancer treatment · Cavities and tooth loss after chemo · Cognitive impairment after brain RT or chemo
Bowel obstruction from adhesions · Urinary retention or incontinence after pelvis RT · Fertility after pelvis, belly, or spine RT · Sexuality after cancer treatment · Cavities and tooth loss after chemo · Cognitive impairment after brain RT or chemo
Bowel obstruction from adhesions · Urinary retention or incontinence after pelvis RT · Fertility after pelvis, belly, or spine RT · Sexuality after cancer treatment · Cavities and tooth loss after chemo · Cognitive impairment after brain RT or chemo
Bowel obstruction from adhesions · Urinary retention or incontinence after pelvis RT · Fertility after pelvis, belly, or spine RT · Sexuality after cancer treatment · Cavities and tooth loss after chemo · Cognitive impairment after brain RT or chemo
Hematologic · cited, not encoded
ACS follow-up tests named here: Yearly thyroid exam after head, neck, or throat radiation · Lung function tests after some chemo or a stem-cell or bone-marrow transplant · Echoes after cardiotoxic chemo · Yearly mammograms plus breast MRIs after chest radiation before age 30
Anthracycline and bleomycin stay unnamed as myeloma-specific.
No invented printout field. Complementary ACS follow-up-care and late-effects pointers stay on this page.
Official copy: there is no standard staging system for leukemia.
ACS follow-up tests named here: Yearly thyroid exam after head, neck, or throat radiation · Lung function tests after some chemo or a stem-cell or bone-marrow transplant · Echoes after cardiotoxic chemo · Yearly mammograms plus breast MRIs after chest radiation before age 30
Anthracycline and bleomycin stay unnamed as myeloma-specific.
Genitourinary · cited, not encoded
ACS follow-up tests named here: Echoes after cardiotoxic chemo
No invented printout field. Complementary ACS follow-up-care and late-effects pointers stay on this page.
ACS follow-up tests named here: Echoes after cardiotoxic chemo
Gynecologic · cited, not encoded
Low estrogen after pelvic treatment · Osteoporosis after hormone-affecting treatment · Low estrogen or testosterone after hormone-affecting treatment · Osteonecrosis of the jaw after bisphosphonates · Vision change after hormone therapy · Lymphedema after pelvic-node surgery or RT
Low estrogen after pelvic treatment · Osteoporosis after hormone-affecting treatment · Low estrogen or testosterone after hormone-affecting treatment · Osteonecrosis of the jaw after bisphosphonates · Vision change after hormone therapy · Lymphedema after pelvic-node surgery or RT
Low estrogen after pelvic treatment · Osteoporosis after hormone-affecting treatment · Low estrogen or testosterone after hormone-affecting treatment · Osteonecrosis of the jaw after bisphosphonates · Vision change after hormone therapy · Lymphedema after pelvic-node surgery or RT
Head, neck, and endocrine · cited, not encoded
No invented printout field. Complementary ACS follow-up-care and late-effects pointers stay on this page.
ACS follow-up tests named here: Yearly thyroid exam after head, neck, or throat radiation
ACS follow-up tests named here: Yearly thyroid exam after head, neck, or throat radiation
Central nervous system · cited, not encoded
ACS follow-up tests named here: Yearly thyroid exam after head, neck, or throat radiation
The cited adult brain after-treatment page still has no official later-cancer sentence.
Other cited sites · cited, not encoded
ACS follow-up tests named here: Echoes after cardiotoxic chemo · Lung function tests after some chemo or a stem-cell or bone-marrow transplant
ACS follow-up tests named here: Echoes after cardiotoxic chemo · Lung function tests after some chemo or a stem-cell or bone-marrow transplant